Zinc supplementation in treatment of obese children and adolescents with nonalcoholic fatty liver disease
Phase 3
- Conditions
- on alcoholic fatty liver disease (NAFLD).Nonalcoholic steatohepatitis (NASH)K75.81
- Registration Number
- IRCT20200531047614N1
- Lead Sponsor
- Kashan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Obese children and adolescents diagnosed with nonalcoholic fatty liver
Patients aged 10-18 years old.
Exclusion Criteria
Taking any antioxidant and/or anti-inflammatory supplements within 3 months prior to the enrollment.
Patients with infectious and autoimmune diseases
Hypersensitivity to the study medication.
Unwillingness to cooperate
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hs-CRP. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Elisa kit.
- Secondary Outcome Measures
Name Time Method Severity of liver steatosis. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Sonography.;Serum liver enzymes. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Enzymatic kit.;LDL. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Enzymatic kit.